Plain-English translation of NCT06579144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial studied , a new blood clotting medication for severe hemophilia A, to understand how long it worked in the body. Researchers compared it directly to two other similar clotting medications (damactocog alfa pegol or turoctocog alfa pegol) that participants were already using. The study measured and compared how quickly the body used up each medication over time.
People with severe hemophilia A need regular clotting medication to prevent dangerous bleeding. Researchers wanted to understand how long this new treatment stays active in the body compared to existing options, to help doctors decide if it could be a better choice for patients.
You would visit the clinic multiple times over several weeks. First, you would receive an injection of your current clotting medication, then blood samples would be taken at 7 follow-up visits to measure how the medication worked. After those samples were complete, you would receive a single injection of the new medication at visit 8, followed by 8 more visits where blood samples were taken to measure how it worked. The entire study took several weeks from start to finish.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Bulgaria
Germany
Italy
Spain